Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Hyundai Motor Shares Surge on Nvidia Partnership Speculation 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Embraer Boosts Aircraft Deliveries in Q4 2025, Signaling Strong Growth Into 2026 
Jollibee Plans U.S. Listing for International Business, Shares Rally 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Barclays Invests in Stablecoin Clearing Firm Ubyx to Advance Digital Money Strategy 
Lenovo Unveils AI Cloud Gigafactory With NVIDIA and Launches New AI Platform at CES 2026 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Baidu’s AI Chip Unit Kunlunxin Prepares for Hong Kong IPO to Raise Up to $2 Billion 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Avelo Airlines to End DHS Deportation Flights and Close Arizona Base Amid Rising Costs 
FDA Limits Regulation of Wearable Devices and Wellness Software, Boosting Health Tech Industry 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
NEWTON, Mass., April 05, 2016 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael G. Kauffmann, MD, PhD, Chief Executive Officer of Karyopharm, is scheduled to present at the upcoming 15th Annual Needham Healthcare Conference in New York City on Tuesday, April 12, 2016 at 8:40 a.m. ET.
A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at http://investors.karyopharm.com/events.cfm. A replay of the webcast will be archived on the company's website for 30 days following the presentation.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Newton, Massachusetts. For more information, please visit www.karyopharm.com.
Contact: Justin Renz (617) 658-0574 [email protected] Gina Nugent (617) 460-3579 [email protected]
